🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Germany / NCT07432945
Recruiting Not applicable

In Vivo Exposure vs. Videochat-Based Vicarious Exposure

NCT07432945 · tracked via the Priya Life Science Germany tracker
Phase
Not applicable
Started
2026-02-26
Last updated
2026-03-02

Condition(s) studied

AnxietyAnxiety Disorders

Investigational drug(s) / intervention(s)

In Vivo Exposure Training (IVET)Vicarious Exposure Training (VicET)

In Vivo Exposure Training (IVET): One session of graded in-vivo exposure with the treated spider. Prior to the exposure, participants receive psychoeducation on spiders, exposure therapy and specific phobia.

Vicarious Exposure Training (VicET): One session of graded video-based vicarious exposure with the treated spider. The steps are modeled by the experimenter. Prior to the exposure, participants receive psychoeducation on spiders, exposure therapy and specific phobia.

Study summary

After screening (including parts of the Mini-DIPS), participants will receive a pre-assessment with a baseline heartrate measurement, self-report measures and two BATs (with the treated spider and the non-treated spider). All participants receive a brief psychoeducation \& video demonstration of exposure steps. Participants are randomly assigned to the three study arms and are then set to receive a single session of either in vivo exposure (IVET), videochat based vicarious exposure (VicET) or neither (Waiting List Control, WLC). Approximately 24 hours later, the two BATs with both spiders, a slightly reduced set of self-report measures and an interview will conduct the post-assessment. The order of all BATs, the spider individuals (treated vs. non-treated spider) and assignment to study arms will be randomized using a list that will be worked through in a sequence determined using "www.random.org". At a six-week follow-up, another long-term assessment will be conducted. Here, participants will receive a brief online questionnaire related to their experiences with spiders and self-report measures that were previously administered. Participants previously assigned to the waiting list control (WLC) will be invited to participate in an in-vivo exposure session. A set of questionnaires including demographic information, VAS scales on the current psychological state and wellbeing (administered at the start and end of the first and second assessment day), the BDI-II, the STAI-T and STAI-S, FEE, SPQ, SBQ, FSQ, GSE, SEQ-SP, TC/E for treatment credibility and the "positive attitudes towards technology subscale" of the MTUA will be used. BDI-II, STAI and MTUA are only administered at pre-assessment. The SAS is used for initial screening.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * Presence of fear of spiders (Potential diagnosis of arachnophobia) Exclusion Criteria: * Reaching level 10 or higher in initial BATs * Any acute or chronic mental disease more debilitating than fear of spiders * Any debilitating acute or chronic somatic disease that prevents or counteracts exposure treatment effects (such as cardiovascular diseases) * Heart Diseases (Pace makers, Bradycardia, Arterial Hypertonia, Heart Arrhythmia) * Psychological, psychiatric, neurological or pharmacological treatment * Drug or alcohol abuse * Pregnancy * Insect Sting Allergy

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Behavioral and Clinical Neuroscience Bochum Germany Recruiting

More Ruhr University of Bochum trials in Germany

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07432945 on ClinicalTrials.gov ↗ ← All trials in Germany